You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSilodosin
Accession NumberDB06207
TypeSmall Molecule
GroupsApproved
DescriptionSilodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.
Structure
Thumb
Synonyms
KAD 3213
KMD 3213
Rapaflo
Urief
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RapafloCapsule4 mg/1OralActavis Pharma, Inc.2009-03-23Not applicableUs
RapafloCapsule8 mgOralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
RapafloCapsule4 mg/1OralAvera Mc Kennan Hospital2015-05-01Not applicableUs
RapafloCapsule8 mg/1OralActavis Pharma, Inc.2009-03-23Not applicableUs
RapafloCapsule8 mg/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs
RapafloCapsule8 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
RapafloCapsule4 mgOralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule4 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
UrorecCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RapilifIpca Urosciences
Silodyx Recordati Industria Chimica e Farmaceutica S.p.A.
UriefWatson Pharmaceuticals Inc.
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICUZ39LUY82
CAS number160970-54-7
WeightAverage: 495.5345
Monoisotopic: 495.234491142
Chemical FormulaC25H32F3N3O4
InChI KeyPNCPYILNMDWPEY-QGZVFWFLSA-N
InChI
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
IUPAC Name
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
SMILES
C[[email protected]](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
Pharmacology
IndicationTreatment for symptomatic relief of benign prostatic hyperplasia
Structured Indications
PharmacodynamicsSilodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval.
Mechanism of actionBenign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Related Articles
AbsorptionQuickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours; AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin.
Volume of distribution

49.5 L

Protein binding97% bound to protein
Metabolism

Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive. Cytochrome P450 CYP 3A4 also generates some metabolites.

Route of eliminationFecal (54.9%); Renal (33.5%)
Half lifeSilodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours;
Clearance

Plasma clearance = 10 L/h

ToxicityMost common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Silodosin.Approved
AcetaminophenThe serum concentration of Silodosin can be increased when it is combined with Acetaminophen.Approved
AdrafinilSilodosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Silodosin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Silodosin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Silodosin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Silodosin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Silodosin can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Silodosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Withdrawn
AmantadineThe serum concentration of Silodosin can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Silodosin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazSilodosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Silodosin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Silodosin can be increased when it is combined with Amprenavir.Approved
AmrinoneSilodosin may increase the hypotensive activities of Amrinone.Approved
AmsacrineThe serum concentration of Silodosin can be increased when it is combined with Amsacrine.Approved
AnisodamineSilodosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Silodosin.Investigational
ApraclonidineSilodosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Silodosin can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineSilodosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolSilodosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Silodosin.Approved
AstemizoleThe serum concentration of Silodosin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Silodosin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Silodosin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Silodosin can be increased when it is combined with Azelastine.Approved
AzelnidipineSilodosin may increase the hypotensive activities of Azelnidipine.Approved
AzimilideSilodosin may increase the hypotensive activities of Azimilide.Investigational
AzithromycinThe serum concentration of Silodosin can be increased when it is combined with Azithromycin.Approved
BarnidipineSilodosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
BenidipineSilodosin may increase the hypotensive activities of Benidipine.Approved
BenzocaineThe serum concentration of Silodosin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BexaroteneThe serum concentration of Silodosin can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Silodosin can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BitolterolSilodosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Silodosin can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BortezomibThe metabolism of Silodosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Silodosin can be increased when it is combined with Bosutinib.Approved
BrimonidineSilodosin may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucindololSilodosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Silodosin.Experimental, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BuprenorphineThe serum concentration of Silodosin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Silodosin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Silodosin can be increased when it is combined with Caffeine.Approved
CaiSilodosin may increase the hypotensive activities of Cai.Investigational
CanagliflozinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Silodosin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Silodosin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Silodosin can be increased when it is combined with Carbamazepine.Approved, Investigational
CarteololCarteolol may increase the orthostatic hypotensive activities of Silodosin.Approved
CarvedilolThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Silodosin can be increased when it is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
CeritinibThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Silodosin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Silodosin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Silodosin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.Approved
CilnidipineSilodosin may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Silodosin can be increased when it is combined with Cimetidine.Approved
CinnarizineSilodosin may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CirazolineSilodosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe serum concentration of Silodosin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Silodosin can be decreased when combined with Clemastine.Approved
ClenbuterolSilodosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineSilodosin may increase the hypotensive activities of Clevidipine.Approved
ClofazimineThe serum concentration of Silodosin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Silodosin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineSilodosin may decrease the vasoconstricting activities of Clonidine.Approved
ClotrimazoleThe serum concentration of Silodosin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Silodosin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Silodosin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Silodosin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Silodosin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Silodosin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Silodosin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Silodosin can be increased when it is combined with Dactinomycin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Silodosin.Investigational
DarodipineSilodosin may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Silodosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Silodosin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Silodosin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Silodosin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.Approved, Investigational
DetomidineSilodosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineSilodosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Silodosin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Silodosin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Silodosin can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Silodosin can be increased when it is combined with Diltiazem.Approved
DipivefrinSilodosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.Approved
DobutamineSilodosin may decrease the vasoconstricting activities of Dobutamine.Approved
DotarizineSilodosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Silodosin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Silodosin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Silodosin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Silodosin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.Approved
DroxidopaSilodosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfavirenzThe serum concentration of Silodosin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineSilodosin may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Silodosin can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Silodosin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Silodosin can be increased when it is combined with Enzalutamide.Approved
EperisoneSilodosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineSilodosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinephrineSilodosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
ErgonovineThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Silodosin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Silodosin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Silodosin.Approved
EstramustineThe serum concentration of Silodosin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Silodosin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Silodosin can be decreased when it is combined with Estrone.Approved
EtilefrineSilodosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Silodosin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Silodosin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Silodosin can be increased when it is combined with Felodipine.Approved, Investigational
FendilineSilodosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoterolSilodosin may decrease the vasoconstricting activities of Fenoterol.Approved
FentanylThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Silodosin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Silodosin can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Silodosin can be increased when it is combined with Fluconazole.Approved
FlunarizineSilodosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Silodosin can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolSilodosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Silodosin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Silodosin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Silodosin can be increased when it is combined with Fusidic Acid.Approved
GabapentinSilodosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilSilodosin may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Silodosin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Silodosin can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Silodosin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Silodosin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Silodosin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Silodosin can be increased when it is combined with Grepafloxacin.Withdrawn
GuanabenzSilodosin may decrease the vasoconstricting activities of Guanabenz.Approved
GuanfacineSilodosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.Approved
HexoprenalineSilodosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineSilodosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocortisoneThe serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Silodosin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Silodosin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Silodosin can be increased when it is combined with Imipramine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Silodosin.Withdrawn
IndinavirThe serum concentration of Silodosin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminSilodosin may increase the antihypertensive activities of Indoramin.Withdrawn
IsavuconazoniumThe serum concentration of Silodosin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineSilodosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsoprenalineSilodosin may decrease the vasoconstricting activities of Isoprenaline.Approved
IsoxsuprineSilodosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Silodosin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Silodosin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Silodosin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Silodosin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Silodosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Silodosin.Approved
LacidipineSilodosin may increase the hypotensive activities of Lacidipine.Approved
LamotrigineSilodosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Silodosin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Silodosin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineSilodosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Silodosin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Silodosin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Silodosin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Silodosin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Silodosin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Silodosin can be increased when it is combined with Lisinopril.Approved, Investigational
LofexidineSilodosin may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Silodosin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Silodosin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Silodosin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Silodosin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Silodosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Silodosin can be decreased when it is combined with Lumacaftor.Approved
Magnesium SulfateSilodosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineSilodosin may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Silodosin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedetomidineSilodosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Silodosin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MephentermineSilodosin may decrease the vasoconstricting activities of Mephentermine.Approved
MeprobamateThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.Approved, Illicit
MetaraminolSilodosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe serum concentration of Silodosin can be increased when it is combined with Methadone.Approved
MethoxamineSilodosin may decrease the vasoconstricting activities of Methoxamine.Approved
MethyldopaSilodosin may decrease the vasoconstricting activities of Methyldopa.Approved
MetoprololThe serum concentration of Silodosin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Silodosin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Silodosin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Silodosin can be increased when it is combined with Midazolam.Approved, Illicit
MidodrineSilodosin may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronSilodosin may decrease the vasoconstricting activities of Mirabegron.Approved
MitomycinThe serum concentration of Silodosin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Silodosin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Silodosin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Silodosin can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Silodosin can be increased when it is combined with Morphine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Silodosin.Approved
NafcillinThe serum concentration of Silodosin can be decreased when it is combined with Nafcillin.Approved
NaftopidilSilodosin may increase the hypotensive activities of Naftopidil.Investigational
NaltrexoneThe serum concentration of Silodosin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineSilodosin may decrease the vasoconstricting activities of Naphazoline.Approved
NaringeninThe serum concentration of Silodosin can be increased when it is combined with Naringenin.Experimental
NebivololSilodosin may decrease the vasoconstricting activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Silodosin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Silodosin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Silodosin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Silodosin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.Approved
NiguldipineSilodosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineSilodosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineSilodosin may increase the hypotensive activities of Nilvadipine.Approved
NimesulideSilodosin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineSilodosin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Silodosin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.Approved
NorepinephrineSilodosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Silodosin can be decreased when it is combined with Norethisterone.Approved
NylidrinSilodosin may decrease the vasoconstricting activities of Nylidrin.Approved
OlaparibThe metabolism of Silodosin can be decreased when combined with Olaparib.Approved
OlodaterolSilodosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmeprazoleThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineSilodosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Silodosin can be increased when it is combined with Osimertinib.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved
OxymetazolineSilodosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
P-NitrophenolThe serum concentration of Silodosin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
PentobarbitalThe metabolism of Silodosin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineSilodosin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe serum concentration of Silodosin can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Silodosin can be increased when combined with Phenobarbital.Approved
PhenylephrineSilodosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineSilodosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Silodosin can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Silodosin can be increased when it is combined with Pimozide.Approved
PinaveriumSilodosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
PirbuterolSilodosin may decrease the vasoconstricting activities of Pirbuterol.Approved
Platelet Activating FactorThe serum concentration of Silodosin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Silodosin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Silodosin.Approved
PravastatinThe serum concentration of Silodosin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Silodosin can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinSilodosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineSilodosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidoneThe metabolism of Silodosin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Silodosin can be increased when it is combined with Probenecid.Approved
ProcaterolSilodosin may decrease the vasoconstricting activities of Procaterol.Approved
ProgesteroneThe serum concentration of Silodosin can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Silodosin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Silodosin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Silodosin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.Approved
PseudoephedrineSilodosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuercetinThe serum concentration of Silodosin can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Silodosin can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Silodosin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Silodosin can be increased when it is combined with Quinine.Approved
RacepinephrineSilodosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineSilodosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RanitidineThe serum concentration of Silodosin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Silodosin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Silodosin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Silodosin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Silodosin can be increased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Silodosin can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Silodosin can be increased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Silodosin can be increased when combined with Rifapentine.Approved
RilmenidineSilodosin may decrease the vasoconstricting activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Silodosin can be increased when it is combined with Rilpivirine.Approved
RisedronateSilodosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RitobegronSilodosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineSilodosin may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Silodosin can be increased when it is combined with Rolapitant.Approved
RomifidineSilodosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
SalbutamolSilodosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolSilodosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Silodosin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Silodosin can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Silodosin.Approved, Investigational
SiltuximabThe serum concentration of Silodosin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Silodosin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Silodosin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Silodosin can be increased when it is combined with Sirolimus.Approved, Investigational
SolabegronSilodosin may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Silodosin can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Silodosin.Approved
SpironolactoneThe serum concentration of Silodosin can be increased when it is combined with Spironolactone.Approved
SR 58611Silodosin may decrease the vasoconstricting activities of SR 58611.Investigational
St. John's WortThe serum concentration of Silodosin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Silodosin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Silodosin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Silodosin can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Silodosin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Silodosin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Silodosin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Silodosin can be increased when it is combined with Sunitinib.Approved, Investigational
SynephrineSilodosin may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineThe serum concentration of Silodosin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Silodosin can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Silodosin.Approved, Investigational
TamoxifenThe serum concentration of Silodosin can be increased when it is combined with Tamoxifen.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Silodosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Silodosin can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Silodosin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Silodosin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.Approved
TerbutalineSilodosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerfenadineThe serum concentration of Silodosin can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Silodosin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Silodosin can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Silodosin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Silodosin.Approved
TizanidineSilodosin may decrease the vasoconstricting activities of Tizanidine.Approved
TocilizumabThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidSilodosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolvaptanThe serum concentration of Silodosin can be increased when it is combined with Tolvaptan.Approved
TranilastSilodosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TrazodoneThe serum concentration of Silodosin can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinSilodosin may increase the antihypertensive activities of Trimazosin.Experimental
TrimethoprimThe serum concentration of Silodosin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Silodosin can be increased when it is combined with Troleandomycin.Approved
TulobuterolSilodosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Silodosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Silodosin.Approved
VenlafaxineThe serum concentration of Silodosin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Silodosin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Silodosin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Silodosin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Silodosin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineSilodosin may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Silodosin can be increased when it is combined with Voriconazole.Approved, Investigational
XylazineSilodosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineSilodosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Silodosin may decrease the vasoconstricting activities of YM-178.Investigational
ZiconotideSilodosin may increase the hypotensive activities of Ziconotide.Approved
ZimelidineThe serum concentration of Silodosin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Silodosin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49%
References
Synthesis ReferenceNot Available
General References
  1. Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. [PubMed:18042003 ]
  2. Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. [PubMed:17603160 ]
External Links
ATC CodesG04CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (846 KB)
MSDSDownload (479 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7383
Caco-2 permeable-0.5847
P-glycoprotein substrateSubstrate0.8467
P-glycoprotein inhibitor INon-inhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.7864
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8226
CYP450 2D6 substrateNon-substrate0.6362
CYP450 3A4 substrateSubstrate0.6585
CYP450 1A2 substrateNon-inhibitor0.7439
CYP450 2C9 inhibitorNon-inhibitor0.7569
CYP450 2D6 inhibitorNon-inhibitor0.5958
CYP450 2C19 inhibitorNon-inhibitor0.5562
CYP450 3A4 inhibitorInhibitor0.7424
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5723
Ames testNon AMES toxic0.6667
CarcinogenicityNon-carcinogens0.8529
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4845 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Inhibitor0.8366
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral4 mg/1
CapsuleOral8 mg/1
CapsuleOral4 mg
CapsuleOral8 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5387603 No1998-12-012018-12-01Us
US5403847 No1992-11-132012-11-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 - 109°CFDA label
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0111 mg/mLALOGPS
logP2.96ALOGPS
logP3.05ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.87ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.05 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity128.92 m3·mol-1ChemAxon
Polarizability49.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolecarboxylic acids and derivatives
Direct ParentIndolecarboxamides and derivatives
Alternative Parents
Substituents
  • Indolecarboxamide derivative
  • Benzamide
  • Dialkylarylamine
  • Phenol ether
  • Benzoyl
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Vinylogous amide
  • 1,3-aminoalcohol
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
  2. Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr: Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. [PubMed:20071497 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. Translocation of PC makes the biliary phospholipids available for extraction into the canaliculi ...
Gene Name:
ABCB4
Uniprot ID:
P21439
Molecular Weight:
141521.845 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on December 02, 2016 02:43